Department of Radiology
Found 8 results
Filters: Author is Pandit-Taskar, Neeta  [Clear All Filters]
2022
Chandler CS, Bell MM, Chung SK, Veach DR, Fung EK, Punzalan B, Vargas DBurnes, Patel M, Xu H, Guo H-F et al..  2022.  Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis.. Mol Cancer Ther. 21(1):125-137.
2021
Yerrabelli RS, He P, Fung EK, Kramer K, Zanzonico PB, Humm JL, Guo H, Pandit-Taskar N, Larson SM, Cheung N-KV.  2021.  IntraOmmaya compartmental radioimmunotherapy using I-omburtamab-pharmacokinetic modeling to optimize therapeutic index.. Eur J Nucl Med Mol Imaging. 48(4):1166-1177.
2019
Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, Zhang Z, Lyashchenko SK, Fung AM, Pentlow KS et al..  2019.  Biodistribution and Dosimetry of Intraventricularly Administered I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.. J Nucl Med. 60(12):1794-1801.
Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, Cheal SM, O'Donoghue JA, Ruan S, Ragupathi G et al..  2019.  Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.. J Nucl Med. 60(11):1517-1523.
O'Donoghue JA, Danila DC, Pandit-Taskar N, Beylergil V, Cheal SM, Fleming SE, Fox JJ, Ruan S, Zanzonico PB, Ragupathi G et al..  2019.  Pharmacokinetics and Biodistribution of a [Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.. Mol Pharm. 16(7):3083-3090.
2016
Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M et al..  2016.  First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.. J Nucl Med. 57(12):1858-1864.
2015
Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AMak et al..  2015.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.. Clin Cancer Res. 21(23):5277-85.
2014
Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gönen M et al..  2014.  ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.. Eur J Nucl Med Mol Imaging. 41(11):2093-105.